Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
FLOXIN is an oral small-molecule tablet approved by the FDA in December 1990 as an NDA from Johnson & Johnson. The specific indication, mechanism of action, and pharmacologic class are not currently documented in available data. Pharma professionals should note this product requires additional research to confirm therapeutic area and patient population.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating team rightsizing and transition planning may be underway.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media in Children
Zero actively linked job postings suggest limited hiring momentum on FLOXIN. This product represents a mature, late-stage career assignment best suited for professionals with lifecycle management, generic defense, or strategic rationalization experience rather than launch-growth expertise.
Worked on FLOXIN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.